Parathyroid Hyperplasia Completed Phase 3 Trials for Denosumab (DB06643)

IndicationStatusPhase
DBCOND0054354 (Parathyroid Hyperplasia)Completed3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03027557Treatment of Primary Hyperparathyroidism With Denosumab and Cinacalcet.Treatment